美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

賽博科技

0.3100

0.0000

成交量：- -

成交額：- -

市值：2,531.03萬

市盈率：-0.15

高：0.3100

開：0.3100

低：0.3100

收：0.3100

52周最高：2.36

52周最低：0.2200

股本：8,164.60萬

流通股本：7,180.60萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.1000

淨資產收益率：--

總資產收益率：--

市淨率：0.16

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Camizestrant與芙仕得相比顯著延緩晚期ER陽性乳腺癌患者疾病進展，延長至少3.5個月患者獲益

KN046聯合白蛋白紫杉醇用於三陰乳腺癌治療的最終研究結果在SABCS 2022公布

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CBR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CBR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBR\",,,,,undefined,":{"symbol":"CBR","market":"US","secType":"STK","nameCN":"賽博科技","latestPrice":0.31,"timestamp":1499101200000,"preClose":0.31,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":71806040,"shares":81646000,"eps":-2.1,"marketStatus":"休市中","change":0,"latestTime":"07-03 13:00:00 EDT","open":0.31,"high":0.31,"low":0.31,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.1,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"listingDate":763880400000,"exchange":"NYSE","adjPreClose":0.31,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBR\",,,,,undefined,":{"symbol":"CBR","floatShares":71806040,"roa":"--","roe":"--","lyrEps":0,"shares":81646000,"dividePrice":0,"high":0.31,"amplitude":0,"preClose":0.31,"low":0.31,"week52Low":0.22,"pbRate":"0.16","week52High":2.36,"institutionHeld":0.7701,"latestPrice":0.31,"eps":-2.1,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.1,"open":0.31,"prevYearClose":0.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CBR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-08","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.06,"name":null,"time":"盤前","type":"earning","dateTimestamp":1478581200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-08-04","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.02,"name":null,"time":"盤前","type":"earning","dateTimestamp":1470283200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-05","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.13,"name":null,"time":"盤前","type":"earning","dateTimestamp":1462420800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-18","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":0.04,"name":null,"time":"盤前","type":"earning","dateTimestamp":1455771600000,"reportTimeType":"pre","actualEps":0.01},{"market":"US","date":"2015-10-29","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":0.03,"name":null,"time":"盤前","type":"earning","dateTimestamp":1446091200000,"reportTimeType":"pre","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CBR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CBR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CBR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2290707862","title":"Camizestrant與芙仕得相比顯著延緩晚期ER陽性乳腺癌患者疾病進展，延長至少3.5個月患者獲益","url":"https://stock-news.laohu8.com/highlight/detail?id=2290707862","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290707862?lang=zh_tw&edition=fundamental","pubTime":"2022-12-12 12:57","pubTimestamp":1670821020,"startTime":"0","endTime":"0","summary":"Camizestrant在没有检测到ESR1突变的患者中也有疗效，75mg和150mg剂量水平下疾病进展或死亡风险分别降低22%和24%。Camizestrant的耐受性普遍良好，其安全性与以前的试验中观察到的一致，没有发现新的安全信号。阿斯利康为评估Camizestrant治疗晚期乳腺癌制定了广泛的临床开发计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3962076_ZH62076_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4203","BK4007","BK4195","PFS","CDK","BK4023","HR","LU0109394709.USD","CBR","LU0320765992.SGD","AZN","LU0889565916.HKD","BK4568"],"gpt_icon":0},{"id":"2290748162","title":"KN046聯合白蛋白紫杉醇用於三陰乳腺癌治療的最終研究結果在SABCS 2022公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2290748162","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290748162?lang=zh_tw&edition=fundamental","pubTime":"2022-12-12 10:30","pubTimestamp":1670812200,"startTime":"0","endTime":"0","summary":"KN046-203的初步研究结果已于2021年在AACR大会线上公开，本次公开的数据是该研究的最终研究结果。研究结果表明，KN046耐受性良好；KN046联合白蛋白结合型紫杉醇对晚期三阴乳腺癌患者有效，无论患者的PD-L1是否阳性，都显示出无进展生存期和总生存期获益。目前KN046四个注册临床试验正在进行中，其中KN046联合化疗一线治疗非小细胞肺癌的Ⅲ期临床研究中期分析成功达到预设PFS终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3962192_ZH62192_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0109391861.USD","BK4550","BK4573","LU0109392836.USD","IE00B19Z9505.USD","LU0444971666.USD","IE00B1XK9C88.USD","LU0353189680.USD","ITT","CBR","IE0009356076.USD","BK4566","LU0097036916.USD","BK4576","LU0056508442.USD","BK4161","BK4532","IE0004445239.USD","LU0289739343.SGD","LU0511384066.AUD","BK4574","09966","IE00B1BXHZ80.USD","IE0004445015.USD","LU0353189763.USD","BK4170","LU0320765059.SGD","BK4553","BK1574","IE00BSNM7G36.USD","BK4527","IE00B3S45H60.SGD","BK4515","LU0456855351.SGD","LU0198837287.USD","BK4575","LU0149725797.USD","IRC","LU0256863811.USD","BK4571","BK4581","BK4533","BK4512","BK4195","IE00BJJMRX11.SGD","BK4534","IE00BJJMRY28.SGD","LU0417517546.SGD","IE00BJTD4V19.USD","LU0234572021.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}